PARERE TRIAL
收藏NIAID Data Ecosystem2026-05-01 收录
官方服务：
资源简介：
Retreatment with anti-EGFR monoclonal antibodies is a promising strategy in patients with RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC) who achieved benefit from previous anti-EGFR exposure, upon exclusion of mutations in RAS/BRAF genes according to circulating tumour DNA (ctDNA) analysis by means of liquid biopsy (LB). This treatment approach is now being investigated in the randomized phase II trial PARERE (NCT04787341).
创建时间：
2024-01-17
